Present and future pharmacotherapy for benign prostatic hyperplasia

Drugs of the Future

Volumn 27, Issue 10, 2002, Pages 973-986

  Doggrell, Sheila A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,3,5 TRIMETHYL 6 [3 [4 (2,3 DIHYDRO 2 HYDROXYMETHYL 1,4 BENZODIOXIN 5 YL)PIPERAZIN 1 YL]PROPYLAMINO] 2,4(1H,3H) PYRIMIDINEDIONE; 4 (3,4 DIFLUOROPHENYL) 6 (METHOXYMETHYL) 2 OXO 1,2,3,4 TETRAHYDROPYRIMIDINE 5 CARBOXYLIC ACID 3 [4 (4 FLUOROPHENYL)PIPERIDIN 1 YL]PROPYLAMIDE; 4 [3 [4 [1 (4 METHYL PHENYL) 3 [4 (2 METHOXYPHENYL)PIPERAZINE 1 YL]PROPOXY]BENZOYL]INDOLE 1 YL]BUTYRIC ACID; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN RECEPTOR ANTAGONIST; ANTIANDROGEN; B 8805 033; BICALUTAMIDE; CERNITIN; DOXAZOSIN; ENDOTHELIN; ESTROGEN; FIDUXOSIN; FINASTERIDE; FLUTAMIDE; GROWTH FACTOR; LEUPRORELIN; NIGULDIPINE; NORADRENALIN; PHOSPHODIESTERASE; PRAZOSIN; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; SILODOSIN; SITOSTEROL; STEROID 5ALPHA REDUCTASE; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZANOTERONE;

ASTHENIA; DRUG MECHANISM; DRUG STRUCTURE; EJACULATION DISORDER; FATIGUE; FRACTURE; HEADACHE; HUMAN; HYPOTENSION; IMPOTENCE; LIBIDO DISORDER; MALE; MINIMALLY INVASIVE SURGERY; ORTHOSTATIC HYPOTENSION; PHYTOCHEMISTRY; PROSTATE HYPERTROPHY; REVIEW; SCORING SYSTEM; SEXUAL DYSFUNCTION; TRANSURETHRAL ELECTROVAPORIZATION; TRANSURETHRAL RESECTION; URINE FLOW RATE; VERTIGO;

EID: 0036820774     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.10.740186     Document Type: Review

References (97)

1. Berry, S.J., Coffey, D.S., Walsh, P.C., Ewing, L.L. The development of human benign prostatic hyperplasia with age. J Urol 1984, 132: 474-9.
2. Kane, S.J., Fields, D.W., Vaughan, E.D. Jr. Medical management of benign prostatic hyperplasia. Urology 1990, 36: 5-12.
3. Gormley, G.J., Stoner, E., Bruskewitz, R.C. et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992, 327: 1185-91.
4. Boyarsky, S. A new look at bladder neck obstruction by the Food and Drug Administration regulators: Guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Gen Urin Surg 1977, 68: 29-32.
5. Marks, L.S., Partin, A.W., Gormley, G.J. Prostrate tissue composition and response in men with symptomatic benign prostatic hyperplasia. J Urol 1997, 157: 2171-8.
6. Rittmaster, R.S., Norman, R.W., Thomas, L.N., Rowden, G. Evidence of atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrin Metal 1996, 81: 814-9.
7. Andersen, J.T., Ekman, P., Wolf, H. et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology 1995, 46: 631-7.
8. Nickel, J.C., Fradet, Y., Boake, R.C. et al. Efficacy and safety of finasteride for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 1996, 155: 1251-9.
9. Hudson, P.B., Boake, R., Trachtenberg, J. et al. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group. Urology 1999, 53: 690-5.
10. Andersen, J.T., Nickel, J.C., Marshall, V.R., Schulman, C.C., Boyle, P. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997, 49: 839-45.
11. McConnell, J.D., Bruskewitz, R., Walsh, P. et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998, 338: 557-63.
12. Cockett, A.T., Aso, Y., Denis, L., Khoury, S. The international prostate symptom score (I-PSS) and quality of life assessment. In: Proceedings of the International Consultation of Benign Prostatic Hyperplasia 1991, 180-1.
13. Barry, M.J., Fowler, F.J. Jn., O'Leary, M.P. et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992, 148: 1549-57.
14. Boyle, P., Gould, A.L., Roehrborn, C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials. Urology 1996, 48: 398-405.
15. Marberger, M.J. Long-term effects of finasteride in patients with benign prostatic hyperplasia: A double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998, 51: 677-86.
16. Carlin, B.I., Bodner, D.R., Spirnak, J.P., Resnick, M.I. Role of finasteride in the treatment of recurrent hematuria secondary to benign prostatic hyperplasia. Prostate 1997, 31: 180-2.
17. Miller, M.I., Puchner, P.J. Effects of finasteride on hematuria associated with benign prostatic hyperplasia: Long-term follow-up. Urology 1998, 51: 237-40.
18. Delakas, D., Lianos, E., Karyotis, I., Cranidis, A. Finasteride: A long-term follow-up in the treatment of recurrent hematuria associated with benign prostatic hyperplasia. Urol Int 2001, 67: 69-72.
19. Hochberg, D.A., Basilote, J.B., Armenaka, N.A. et al. Decreased suburethral prostatic microvessel density in finasteride treated prostates: A possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol 2002, 167: 1731-4.
20. Matzkin, H., Barak, M., Braf, Z. Effect of finasteride on free and total serum prostate-specific antigen in men with benign prostatic hyperplasia. Br J Urol 1996, 78: 405-8.
21. Oesterling, J.E., Roy, J., Agha, A. Biological variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: Effects of finasteride, The Finasteride PSA Study Group. Urology 1997, 50: 13-8.
22. Andriole, G.L., Guess, H.A., Epstein J.I. et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: Results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998, 52: 195-201.
23. Yang, X.J., Lecksell, K., Short, K. et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999, 53: 696-700.
24. Matsumoto, A.M., Tenover, L., McClung, M. et al. The long-term effect of specific type II 5α-reductase inhibition with finasteride on bone mineral density in men: Results of a 4-year placebo controlled trial. J Urol 2002, 167: 2105-8
25. 1-Adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 1999, 161, 2002-8.
26. Lin, V.K., Benaim, E.A., McConnell, J.D. α-Blockade down-regulates myosin heavy chain gene expression in human benign prostatic hyperplasia. Urology 2001, 57, 170-5.
27. Lepor, H., Auerbach, S., Puras-Baez, A. et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992, 148: 1467-74.
28. Lepor, H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 1995, 45: 406-13.
29. Elhilali, M.M., Ramsey, E.W., Barkin, J. et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology 1996, 47: 335-42.
30. Roehrborn, C.G., Oesterling, J.E., Auerback, S. et al. The Hytrin Community Assessment Trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 1996, 47: 159-68.
31. Boyle, P., Robertson, C., Mariski, R., Padley, R.J., Roehrborn, C.G. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 2001, 58: 717-22.
32. Roehrborn, C.G., Oesterling, J.E., Olson, P.J., Padley, R.J. Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial. Urology 1997, 50: 556-61.
33. Lepor, H., Williford, W.O., Barry, M.J. et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996, 335: 533-9.
34. Lepor, H., Jones, K., Williford, W. The mechanism of adverse events associated with terazosin: An analysis of the Veterans Affairs Cooperative Studies. J Urol 2000, 163: 1134-7.
35. Lepor, H., Williford, W.O., Barry, M.J., Haakenson, C., Jones, K. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J Urol 1998, 160: 1358-67.
36. Djavan, B., Seitz, C., Roehrborn, C.G. et al. Targeted transurethral microwave thermotherapy versus alpha blockade in benign prostatic hyperplasia: Outcomes at 18 months. Urology 2001, 57: 66-70.
37. Fawzy, A., Braun, K., Lewis, G.P., Gaffney, M., Ice, K., Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study. J Urol 1995, 154: 105-9.
38. Gillenwater, J.Y., Conn, R.L., Chrysant S.G. et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate hypertension: A double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995, 154: 129-30.
39. Lepor, H., Kaplan, S.A., Klimberg, I. et al. Doxazosin for benign prostatic hyperplasia: Long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J Urol 1997, 157: 525-30.
40. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The Antihypertensive and Lip-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000, 283: 1967-75.
41. 1-antagonist therapy and occurrence of hypotensive-related adverse events among men with benign prostatic hyperplasia: A retrospective cohort study. Clin Ther 2001, 23: 727-43.
42. Roehrborn, C.G. Alfuzosin: Overview of pharmacokinetics, safety, and efficacy of a clinically uroselective α-blocker. Urology 2001, 58 (Suppl. 6A): 55-64.
43. Jardin, A., Bensadoun, H., Delauche-Cavallier, M.G., Attali, P. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet 1991, 337: 1457-61.
44. Lukacs, B., Leplege, A., Thibault, P., Jardin, A. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 1996, 48: 731-40.
45. Buzelin, J.M., Roth, S., Geffriaud-Ricouard, C., Delauche-Cavallier, M.C. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. Eur Urol 1997, 31: 190-8.
46. Roehrborn, C.G. Efficacy and safety of once-daily alfuzosin in the treatment of lower tract symptoms and clinical benign prostatic hyperplasia: A randomized, placebo-controlled trial. Urology 2001, 58: 953-9.
47. 1-adrenoceptors: Binding, functional and in vivo studies. Br J Pharmacol 1996, 118: 871-8.
48. 1c-adrenoceptor antagonist: A randomized, controlled trial in patients with benign prostatic "obstruction" (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 1995, 76: 325-36.
49. Lepor, H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998, 51: 901-6.
50. Narayan, P., Lepor, H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001, 57: 466-70.
51. Schulman, C.C., Lock, T.M., Buzelin, J.M. et al. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol 2001, 166: 1358-63.
52. Buzelin, J.M., Fonteyne, E., Kontturi, M., Witjes, W. P., Khan, A. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br J Urol 1997, 80: 597-605.
53. 1A-adreoreceptor antagonists in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 1997, 80: 606-11.
54. 1-adrenoceptor antagonist with uroselective properties. J Pharmacol Exp Ther 2002, 300: 478-86.
55. 1D-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs. J Pharmacol Exp Ther 2002, 300: 487-94.
56. 1A-adrenergic receptor subtype-selective antagonists. J Pharmacol Exp Ther 2000, 294: 244-9.
57. 1A receptor antagonists for the treatment of benign prostatic hyperplasia. J Med Chem 43, 2703-18.
58. 1-adrenoceptor antagonist, in human prostate and vasculature. J Urol 2000, 164: 578-83.
59. 1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs. Int J Urol 2001, 8: 177-83.
60. 1D-adrenoceptors. Naunyn Schmied Arch Pharmacol 2001, 363: 649-62.
61. 1-adrenoceptor antagonistic and steroid 5alpha-reductase inhibitory actions. Naunyn Schmied Arch Pharmacol 1999, 359: 433-8.
62. Bales, G.T., Christiano, A.P., Kirsch, E.J., Gerber, G.S. Phytotherapeutic agents in the treatment of lower urinary tract symptoms: A demographic analysis of awareness and use at the University of Chicago. Urology 1999, 54: 86-9.
63. Wilt, T.J., Ishani, A., Stark, G., MacDonald, R., Lau, J., Mulrow, C. Saw palmetto extracts for treatment of benign prostatic hyperplasia - A systematic review. JAMA 1998, 280: 1604-609.
64. Wilt, T., MacDonald, R., Ishani, A., Rutks, I., Stark, G. Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000, CD001042.
65. Ishani, A., MacDonald, R., Nelson, D., Rutks, I. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: A systematic review and quantitative meta-analysis. Am J Med 2000, 109: 654-64.
66. Lowe, F.C., Ku, J.C. Phytotherapy in treatment of benign prostatic hyperplasia: A critical review. Urology 1996, 48: 12-20.
67. Δ5-3β-hydroxy steroid dehydrogenase and prostatic 5α-reductase activities in rats and humans by strogen forte extract. Int Urol Nephrol 1996, 28: 337-48.
68. Marks, L.S., Partin, A.W., Epstein, J.I. et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000, 163: 1451-6.
69. Marks, L.S., Hess, D.L., Dorey, F.J. et al. Tissue effects of saw palmetto and finasteride: Use of biopsy cores for in situ quantification of prostatic androgens. Urology 2001, 57: 999-1005.
70. Bayne, C.W., Donnelly, F., Ross, M., Habib, F.K. Serenoa repens (Permixon): A 5α-reductase types I and II inhibitor -New evidence in a coculture model of BPH. Prostate 1999, 40: 232-41.
71. Di Silverio, F., Monti, S., Sciarra, A. et al. Effect of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998, 37: 77-83,
72. Kondas, J., Philipp, V., Dioszeghy, G. Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia. Int Urol Nephrol 1996, 28: 767-72.
73. Boyle, P., Robertson, C., Lowe, F., Roehrborn, C. Metaanalysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000, 55: 533-9.
74. Wilt, T., Ishani, A., Stark, G., MacDonald, R., Mulrow, C., Lau, J. Serenoa repens for benign prostatic hyperplasia. Cochrane Database System Rev 2000, CD001423.
75. Carraro, J.C., Raynaud, J.P., Koch, G. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1098 patients. Prostate 1996, 29: 231-40.
76. Berges, R.R., Windeler, J., Trampisch, H.J., Senge, T. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. β-Sitosterol Study Group. Lancet 1995, 345: 1529-32.
77. Kadow, C., Abrams, P.H. A double-blind trial of the effect of β-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia. Eur Urol 1986, 12: 187-9.
78. Habib, F.K., Ross, M., Buck, A.C., Ebeling, L. Lewenstein, A. In vitro evaluation of the pollen extract, cernitin T-60, in the regulation of prostate cell growth. Br J Urol 1990, 66: 393-7.
79. Buck, A.C., Cox, R., Rees, R.W., Ebeling, L., John, A. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study. Br J Urol 1990, 66: 398-404.
80. Gomes, C.M., Disanto, M.E., Horan, P., Levin, R.M., Wein, A.J., Chacko, S. Improved contractility of obstructed bladders after Tadenan treatment is associated with reversal of altered myosin isoforms expression. J Urol 2000, 163: 2008-13.
81. Harada, M., Kinoshita, Y., Moriyama, M. et al. Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA). Prostate 1994, 25: 147-55.
82. Berger, B.N., Naadimuthu, A., Broddy, A. et al. The effect of zanoterone, a steroidal androgen receptor antagonist, in men with benign prostatic hyperplasia. The Zanoterone Study Group. J Urol 1995, 154: 1060-4.
83. Narayan, P., Trachtenberg, J., Lepor, H. et al. A dose-response study of the effect of flutamide on benign prostatic hyperplasia: Results of a multicenter study. Urology 1996, 47: 497-504.
84. Eri, L.M., Haug, E., Tveter, K.J. Effects on the endocrine system of long-term treatment with the non-steroidal anti-androgen Casodex in patients with benign prostatic hyperplasia. Br J Urol 1995, 75: 335-40.
85. Steers, W. D. 5α-Reductase activity in the prostate. Urology 2001, 58: (6 Suppl. 1): 17-24.
86. Ishigooka, M., Yazawa, H., Nakaa, T., Zermann, D.H. Area density of smooth muscle cells and response to endothelin 1 in human hyperplastic prostate. Eur Urol 2000, 37: 494-8.
87. Sciarra, F. Sex steroid and epidermal growth factor in benign prostatic hyperplasia. Ann NY Acad Sci 1995, 761: 66-78.
88. Monti, S., Sciarra, F., Adamo, M.V. et al. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide. J Androl 1997, 18: 488-94.
89. Saez, C., Gonzalez-Baena, A.C., Japon, M.A. et al. Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride. Prostate 1999, 40: 83-8.
90. Comaru-Schally, A.M., Brannan, W., Schally, A.V., Colcolough, M., Monga, M. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab 1998, 83: 3828-31.
91. Radlmaier, A., Eickenberg, H.U., Fletcher, M.S. et al. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: Results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Prostate 1996, 29: 199-208.
92. Denis, L., Pagano, F., Nonis, A., Roberson, C., Romano, P., Boyle, P. Double-blind, placebo-controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPH. Prostate 1998, 37: 246-52.
93. Brown, L., Hoong, I., Doggrell, S.A. The heart as a target for oestrogens. Heart, Lung and Circulation 2000, 9: 113-25.
94. Takeda, M., Tang, R., Shapiro, E., Burnett, A.L., Lepor, H. Effects of nitric oxide on human and canine prostates. Urology 1995, 45: 440-6.
95. Gradini, R., Realacci, M., Ginepri, A. et al. Nitric oxide synthases in normal and benign hyperplastic human prostate: Immunohistochemistry and molecular biology. J Pathol 1999, 189: 224-9.
96. Drescher, P., Eckert, R.E., Madsen, P.O. Smooth muscle contractility in prostatic hyperplasia: Role of cyclic adenosine monophosphate. Prostate 1994, 25: 76-80.
97. Uckert, S., Kuthe, A., Jonas, U., Stief, C.G. Characterization and functional relevance of cyclic nucleotide phophodiesterase isoenzymes of the human prostate. J Urol 2001, 166: 2484-90.